Diagnosing Alzheimer's Disease Using Biomarkers ID: 2014-064
A breakthrough method for early diagnosis of Alzheimer's disease through serum biomarkers.
Photo by starlineart - stock.adobe.com
Technology Overview
This technology encompasses a pioneering approach for the early detection of Alzheimer's disease (AD) by identifying specific serum biomarkers. Developed through comprehensive studies at Brigham Young University, it leverages advanced proteomics and mass spectrometry techniques to distinguish AD patients from controls. The method has successfully identified four key biomarkers with high diagnostic accuracy, promising a significant leap forward in AD diagnosis and management.
Key Advantages
- Early detection of Alzheimer's disease, potentially even before symptoms appear
- High diagnostic accuracy through the identification of four key serum biomarkers
- Non-invasive testing method using serum samples
- Enables better patient management and treatment planning at early stages of AD
- Supports further research into the pathogenesis and treatment of Alzheimer's disease
Problems Addressed
- Difficulty in diagnosing Alzheimer's disease at an early stage
- Reliance on invasive or less accurate diagnostic methods
- Lack of specific biomarkers for accurate and early diagnosis of AD
- Challenges in patient management due to late diagnosis
Market Applications
- Clinical diagnostics for early detection of Alzheimer's disease
- Pharmaceutical research and development, particularly in targeted therapy for AD
- Healthcare screening programs for at-risk populations
- Development of personalized medicine approaches for Alzheimer's disease
Additional Information
Technology ID: 2014-064
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 06 May, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report